Imperial Brands invests in cannabis-based medical research

LONDON (Reuters) – Tobacco company Imperial Brands is investing in Oxford Cannabinoid Technologies, to help the British biotech company research how marijuana can be used in medicine.

The maker of Gauloises and Winston cigarettes said on Thursday that its subsidiary, Imperial Brands Ventures, was taking an equity stake in the British company. It did not disclose the size of the stake.

The investment comes a year after Imperial named an expert in medicinal cannabis to its board of directors and shows how big tobacco companies are trying to diversify away from the shrinking tobacco market.

It also comes days after the U.S. Food and Drug Administration approved the use of a cannabis-based drug for the first time, a move seen as opening floodgates for more research into the medicinal properties of cannabis.

The Series A funding round also includes Casa Verde Capital and other family offices.

Reporting by Martinne Geller; Editing by Elaine Hardcastle

Continue reading at

About Reuters

Since 1850, we have experimented, invented, and created content and news solutions to become the world’s leading international news agency. Always at the forefront of real-time breaking news and high-impact global multimedia content, we are constantly innovating our products and services to meet your business needs. Whether we are serving broadcasters, publishers, brands, agencies, or direct to consumers, Reuters provides award-winning coverage of the day’s most important topics, including: business, finance, politics, sports, entertainment, technology, health, environment, and much more.